Skip to contentS
Surgery Partners, Inc.
S
SGRYSurgery Partners, Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$864.40M$864.40Mderived+17.5% vs Q4 2023 Net Income-$108.50M-$108.50MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Surgery Partners, Inc. · CIK 1638833 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived$127,100,000+25.3% Operating Cash Flowderived$111,400,000+78.0% Free Cash Flowderived$89,100,000+108.2% Margins · derivedOperating margin14.7%+0.9 pt vs Q4 2023
Net margin-12.6%−12.4 pt vs Q4 2023
ended Dec 31, 2024 · filed Mar 7, 2025 · 66 d after period end